Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 studyCarlo Visco, Monica Balzarotti, Riccardo Bomben et al.|The Lancet Haematology|2025Cited by 6
<i>TP53</i>, <i>CD36</i> Mutations and <i>CDKN2A</i> Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 TrialRiccardo Moia, Carlo Visco, Maria Elena Carazzolo et al.|Blood|2024Cited by 3
Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trialRiccardo Moia, Monica Balzarotti, Mohammad Almasri et al.|Blood Advances|2026Cited by 0